QTRX Quanterix Corporation
USHealthcareAs of 2026-07-10 16:00
Why QTRX matters now
Quanterix Corporation (QTRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.88 with -2.51% on the session and $182.8M in market capitalization; recent performance reads 1-month +35.06% and YTD -46.70%.
The latest financial table shown here is Q1 2026, with revenue of $36.4M, net income of $-17.5M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -51.9%.
The latest indexable market news headline is "Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $4.00; recent insider activity includes Miller Michael Francis filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.56
P/S
1.10
EV/EBITDA
-1.88
DCF Value
$-20.82
FCF Yield
-51.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
44.1%
Operating Margin
-82.7%
Net Margin
-71.9%
ROE
-35.2%
ROA
-28.4%
ROIC
-36.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $36.4M | $-17.5M | $-0.37 |
| Q4 2025 | $43.9M | $-23.1M | $-0.49 |
| FY 2025 | $138.7M | $-107.2M | $-2.51 |
| Q3 2025 | $40.1M | $-33.5M | $-0.73 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.12
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.